Eli Lilly and Company’s incretin drug tirzepatide is playing catch-up to Novo Nordisk A/S’s semaglutide in many disorders. In obese patients with obstructive sleep apnea, however, it is ahead of the competition, and new data from the pivotal SURMOUNT-OSA trial suggest that tirzepatide might amount to a cure in some of these patients.
Key Takeaways
- New SURMOUNT-OSA data show that Lilly’s tirzepatide allowed some obese obstructive sleep apnea patients to have resolution of the condition.
- The benefit seems to be solely driven...
SURMOUNT-OSA had been toplined a hit on its primary endpoint in April, with tirzepatide at either 10mg or 15mg for one year significantly reducing patients’ scores on the apnea-hypopnea index...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
